BioVenic offers one-stop solutions for veterinary vaccine development for protecting animals against various pathogen type.
— The veterinary medical field is increasingly being challenged by new pathogens, increasing antimicrobial resistance, and challenges associated with traditional vaccine approaches. Many traditional vaccines are time-consuming to develop, raise issues concerning their safety, and provide variable protection for different species. DNA vaccines have shown promise but have been plagued by poor immune stimulation and inefficient delivery.
Recently, BioVenic has introduced an integrated phage-based vaccine development product that incorporates phage display, phage DNA, and phage-based hybrid approaches into a single, start-to-finish process.
“Bacteriophages, highly appreciated as model organisms in biotechnology, start to reveal themselves as efficient vaccine carriers because of their intrinsic safety, flexibility, and adjuvant properties,” said an expert at BioVenic.
One of the important issues under investigation in today’s vaccine research is finding an effective approach for antigen presentation to induce efficient immunostimulation in different animal models. In this regard, BioVenic’s phage display platform directly supports efficient, high-density antigen presentation to the surface of filamentous, T4, T7, or λ phages, thus not only promoting an effective immunostimulatory response, but rapidly identifying potential antigens via biopanning or sequencing.
“Another challenge often mentioned by veterinary scientists is the need for safer gene delivery methods that do not rely on the toxicity associated with conventional DNA vaccines,” added the scientist.
In response to this challenge, BioVenic’s phage DNA vaccine platform for veterinary uses non-replicating phage particles to carry DNA encoding antigens in eukaryotic expression vectors. This approach increases efficiency of delivery with an excellent safety profile, ensured by stringent purification, endotoxin removal, electron microscopy analysis, and in vitro, as well as in vivo, analyses for immuno génicities.
However, perhaps the most important question within the current state of immunology is that of achieving both rapid activation and long-term immunity without the need for extensive adjuvant components. BioVenic has rich project service experience in the development of hybrid phage veterinary vaccines.
The hybrid phages have a clear solution for achieving both rapid and long-term immune activation and immunity with the use of surface-expressed antigens and the incorporation of full-length antigen genes within the same phage particles, which directly addresses the concerns and ineffectiveness that exist within current DNA vaccines for the control of bacterial and viruses within animals.
Learn more, please visit https://www.biovenic.com/.
About BioVenic
BioVenic is a global biotechnology solutions provider specializing in advanced veterinary vaccine development. With extensive expertise in phage‑based technologies and a full suite of R&D, testing, and manufacturing capabilities, BioVenic empowers researchers and companies to accelerate innovation from concept to commercialization.
Contact Info:
Name: Ashley Hutt
Email: Send Email
Organization: BioVenic
Website: https://www.biovenic.com/
Release ID: 89181374
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.